Genenta S.p.A. (GNTA) IPO Opens 13% Lower

Today's IPO for Genenta S.p.A. (NASDAQ: GNTA) opened for trading at $10.05 after pricing 2.4 million American Depositary Shares, or ADSs, each representing one ordinary share, at a public offering price of $11.50 per share.

Roth Capital Partners is acting as sole book-running manager of the offering. Maxim Group LLC is acting as lead manager of the offering.

Genenta Science Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.

You May Also Be Interested In

• Attovia Therapeutics prices IPO at $17 per share on Nasdaq
• Elong Power prices $1.38M public offering at $0.12 per unit
• East West Ave Acquisition Corp. closes $100M IPO on Nasdaq